COR · CENCORA, INC. · Top AI ETF

Back to holdings

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S.

Close · 3M

+9.42%

Held by 1 AI ETF

AIEQ0.050%

as of Sep 4

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals3

Win rate100% (3/3)

Avg buy return+20.12%

AIEQnow 0.050% of fund5 signals

AIEQ · Weight decrease · 2d

weight 0.400% → 0.050% (-0.350 pp)·stock up 9.0% in the 30 days before

Jul 1·entry $288.42·now $337.22

+16.92%

since Jul 1

AIEQ · Weight increase · 2d

weight 0.370% → 0.400% (+0.030 pp)·stock up 6.0% in the 30 days before

Jun 25·entry $286.95·now $337.22Chased

+17.52%

since Jun 25

AIEQ · Weight increase · 2d

weight 0.380% → 0.400% (+0.020 pp)·stock up 7.9% in the 30 days before

Jun 11·entry $281.48·now $337.22Chased

+19.80%

since Jun 11

AIEQ · Weight increase · 2d

weight 0.360% → 0.380% (+0.020 pp)·stock up 8.8% in the 30 days before

Jun 7·entry $274.08·now $337.22Chased

+23.04%

since Jun 7

AIEQ · Sudden change · 1d

weight 0.610% → 0.270% (-0.340 pp)·stock down 4.3% in the 30 days before

May 3·entry $303.66·now $337.22

+11.05%

since May 3

AMOMno longer held14 signals

AMOM · Exit · 1d

weight 1.150% → 0 (exited)·stock down 6.5% in the 30 days before

May 4·entry $303.66·now $337.22

+11.05%

since May 4

AMOM · Weight decrease · 2d

weight 1.210% → 1.150% (-0.060 pp)·stock down 4.3% in the 30 days before

May 1·entry $304.00·now $337.22

+10.93%

since May 1

AMOM · Weight decrease · 7d

weight 1.320% → 1.200% (-0.120 pp)·stock down 3.8% in the 30 days before

Apr 22·entry $308.30·now $337.22

+9.38%

since Apr 22

AMOM · Weight decrease · 7d

weight 1.350% → 1.230% (-0.120 pp)·stock down 4.4% in the 30 days before

Apr 21·entry $312.39·now $337.22

+7.95%

since Apr 21

AMOM · Weight decrease · 7d

weight 1.390% → 1.260% (-0.130 pp)·stock down 2.6% in the 30 days before

Apr 20·entry $323.01·now $337.22

+4.40%

since Apr 20

AMOM · Weight decrease · 7d

weight 1.400% → 1.270% (-0.130 pp)·stock up 0.7% in the 30 days before

Apr 17·entry $327.56·now $337.22

+2.95%

since Apr 17

AMOM · Weight decrease · 7d

weight 1.420% → 1.270% (-0.150 pp)·stock down 3.7% in the 30 days before

Apr 16·entry $322.37·now $337.22

+4.61%

since Apr 16

AMOM · Weight decrease · 6d

weight 1.420% → 1.290% (-0.130 pp)·stock down 8.2% in the 30 days before

Apr 15·entry $317.58·now $337.22

+6.18%

since Apr 15

AMOM · Weight decrease · 5d

weight 1.420% → 1.310% (-0.110 pp)·stock down 8.4% in the 30 days before

Apr 10·entry $320.82·now $337.22

+5.11%

since Apr 10

AMOM · Weight decrease · 4d

weight 1.420% → 1.320% (-0.100 pp)·stock down 8.4% in the 30 days before

Apr 9·entry $322.46·now $337.22

+4.58%

since Apr 9

AMOM · Weight decrease · 3d

weight 1.420% → 1.350% (-0.070 pp)·stock down 10.2% in the 30 days before

Apr 8·entry $324.93·now $337.22

+3.78%

since Apr 8

AMOM · Weight decrease · 2d

weight 1.420% → 1.390% (-0.030 pp)·stock down 10.5% in the 30 days before

Apr 7·entry $320.89·now $337.22

+5.09%

since Apr 7

AMOM · Weight decrease · 2d

weight 1.230% → 1.180% (-0.050 pp)·stock down 14.5% in the 30 days before

Apr 1·entry $317.66·now $337.22

+6.16%

since Apr 1

AMOM · Weight decrease · 2d

stock down 7.9% in the 30 days before

Mar 19·entry $331.74·now $337.22

+1.65%

since Mar 19

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Fails the frameworkas of May 2

The AI ETFs, particularly AMOM, are showing a recent trend of decreasing their weight in Cencora. This activity aligns with the framework's 'Fail' verdict, suggesting smart money might also be detecting concerns about the company's valuation or financial sustainability at current prices.

Circle of CompetenceThe pharmaceutical distribution industry, while complex, has stable unit economics and a predictable role in the healthcare supply chain, allowing for reasonable projection of future cash flows.
Economic MoatCencora benefits from a strong scale-driven cost advantage in pharmaceutical distribution, high switching costs for customers, and established logistical networks that create a durable economic moat.
ManagementManagement's candor, capital allocation discipline, and skin in the game cannot be assessed with the provided financial snippets.
Financial HealthThe exceptionally high single-year ROE of 101.43% suggests a highly leveraged capital structure or a very small equity base, raising concerns about 'undue leverage' and preventing a confident assessment of long-term financial health without more detailed balance sheet and historical performance data.
Margin of SafetyThe current valuation multiples, including a PER of 37.12 and PBR of 40.18, indicate a high market valuation relative to earnings and book value, suggesting no discernible margin of safety at the current price.

Cencora operates within a stable industry and possesses a strong economic moat due to its scale and entrenched position. However, the available financial data, particularly the exceptionally high single-year ROE without context on leverage, prevents a confident assessment of its financial health. Furthermore, the current valuation multiples suggest the stock is trading at a significant premium, leaving no margin of safety for investors.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.